Literature DB >> 8879978

The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells.

B Legallicier1, C Leclere, C Monteil, V Elkaz, J P Morin, J P Fillastre.   

Abstract

There is a large scope for the use for cisplatin and its derivatives in the treatment of human malignancies. Nephrotoxicity is their most important use-limiting factor. The aim of this study has been to compare cisplatin (CDDP) and oxaliplatin (1-OHP), a new derivative, on cultures of tubular proximal cells. Three cells models were used: primary culture of rabbit kidney, proximal tubular cells (RPTC) and established opossum kidney (OK) and pig kidney (LLC-PK1) epithelial cell lines. Results indicate that in these three culture systems, the cytotoxicity-ranking of the two molecules were in agreement with their in vivo nephrotoxicity (CDDP > 1-OHP), but were less cytotoxic for OK and LLC-PK1 cells than for RPTC. Functional and biochemical evaluations in RPTC indicate that toxic effects of platinum derivates are exerted on DNA, protein synthesis and glucose uptake. 1-OHP effect on DNA synthesis seems to be more effective, but induced a more progressive cytotoxicity. Alteration of glutathione-dependent detoxication activities may reflect the occurrence of a lipid peroxidation process. The present study showed that 1) RPTC are more suitable that LLC-PK1 or OK cells for investigating the nephrotoxicity of platinum derivatives; 2) 1-OHP seems to have a more powerful pharmacological effect than CDDP. The toxic effect ratio seems to promise greater safety with 1-OHP than with CDDP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879978

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  3 in total

1.  LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway.

Authors:  Jie Liu; Xue-Qiong Fu; Wei Zhou; Hong-Gang Yu; Jie-Ping Yu; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

2.  Cisplatin nephrotoxicity: molecular mechanisms.

Authors:  Marie H Hanigan; Prasad Devarajan
Journal:  Cancer Ther       Date:  2003

3.  Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.

Authors:  Joseph I Clark; Joshua B Greene; Ann Lau Clark; Jay S Dalal; Craig C Hofmeister
Journal:  Med Oncol       Date:  2012-12-25       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.